StockData
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30
$9.20+0.07 (+0.77%)

Close on Nov 17, 2026Market cap $821.53MP/E –Yield –

Syndax Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Syndax Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$177.36M. For fiscal 2025 it was -$322.98M. The highest annual figure on record is $29.13M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$322.98M–
FY2024Dec 31, 2024-$274.90M–
FY2023Dec 31, 2023-$160.60M–
FY2022Dec 31, 2022-$133.68M-558.9%
FY2021Dec 31, 2021$29.13M–
FY2020Dec 31, 2020-$71.26M–
FY2019Dec 31, 2019-$50.61M–
FY2018Dec 31, 2018-$68.53M–
FY2017Dec 31, 2017-$47.37M–
FY2016Dec 31, 2016-$35.16M–
FY2015Dec 31, 2015-$2.43M–
FY2014Dec 31, 2014-$14.39M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$27.25M–
Q2 FY2026Jun 30, 2026-$30.27M–
Q1 FY2026Mar 31, 2026-$50.35M–
Q4 FY2025Dec 31, 2025-$69.49M–
Q3 FY2025Sep 30, 2025-$70.54M–
Q2 FY2025Jun 30, 2025-$87.80M–
Q1 FY2025Mar 31, 2025-$95.16M–
Q4 FY2024Dec 31, 2024-$57.39M–
Q3 FY2024Sep 30, 2024-$62.32M–
Q2 FY2024Jun 30, 2024-$71.65M–
Q1 FY2024Mar 31, 2024-$83.55M–
Q4 FY2023Dec 31, 2023-$41.35M–
Q3 FY2023Sep 30, 2023-$44.65M–
Q2 FY2023Jun 30, 2023-$35.37M–
Q1 FY2023Mar 31, 2023-$39.23M–
Q4 FY2022Dec 31, 2022-$22.89M-122.7%
Q3 FY2022Sep 30, 2022-$28.54M–
Q2 FY2022Jun 30, 2022-$40.31M–
Q1 FY2022Mar 31, 2022-$41.93M–
Q4 FY2021Dec 31, 2021$100.71M–
Q3 FY2021Sep 30, 2021-$24.94M–
Q2 FY2021Jun 30, 2021-$24.05M–
Q1 FY2021Mar 31, 2021-$22.59M–
Q4 FY2020Dec 31, 2020-$15.63M–
Q3 FY2020Sep 30, 2020-$18.30M–
Q2 FY2020Jun 30, 2020-$21.41M–
Q1 FY2020Mar 31, 2020-$15.93M–
Q4 FY2019Dec 31, 2019-$12.73M–
Q3 FY2019Sep 30, 2019-$8.53M–
Q2 FY2019Jun 30, 2019-$12.53M–
Q1 FY2019Mar 31, 2019-$16.83M–
Q4 FY2018Dec 31, 2018-$15.04M–
Q3 FY2018Sep 30, 2018-$18.47M–
Q2 FY2018Jun 30, 2018-$15.15M–
Q1 FY2018Mar 31, 2018-$19.87M–
Q4 FY2017Dec 31, 2017-$12.72M–
Q3 FY2017Sep 30, 2017-$10.18M–
Q2 FY2017Jun 30, 2017-$11.80M–
Q1 FY2017Mar 31, 2017-$12.67M–
Q4 FY2016Dec 31, 2016-$10.42M–

More Syndax Pharmaceuticals figures

See a number that looks wrong?